An Antioxidant, Probucol, Induces Anti-angiogenesis and Apoptosis in Athymic Nude Mouse Xenografted Human Head and Neck Squamous Carcinoma Cells

Goshi Nishimura,¹, ³ Syunsuke Yanoma,² Hiromi Mizuno,¹ Koji Kawakami¹ and Mamoru Tsukuda¹

¹Department of Otorhinolaryngology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 and ²Research Institute of Kanagawa Cancer Center, 1-2-1 Nakao, Asahi-ku, Yokohama 241-0815

Probucol is a very strong synthetic antioxidant that was been safely used for the treatment of hyperlipidemia in Japan since 1985. It has been reported that lipid oxidation products can alter growth factor production, which could influence smooth muscle cell proliferation. Oxidized low density lipoprotein can influence smooth muscle cell proliferation by enhancing the expression of platelet-derived growth factor (PDGF)-AA gene and PDGF receptor in vascular smooth muscle cell. Further, free radical reactions can cause irreversible alterations of genomic constituents during the initiation phase of carcinogenesis. Antioxidant is considered to protect lipids and low density lipoprotein (LDL) from oxidation, which potentially inhibits angiogenesis, and rapid removal of free radicals by antioxidants could have an anti-carcinogenic effect. In the present study, we investigated whether antioxidant treatment with probucol had an antitumor effect on KB cells, a human head and neck squamous carcinoma cell line. Probucol did not have any effect on KB cells in vitro, but probucol treatment of KB cells xenografts in mice had a significant antitumor effect through anti-angiogenic and apoptosis-inducing actions. These results support the idea that probucol is useful for preventing and/or treating cancer.

Key words: Anti-oxidant — Head and neck squamous cell carcinoma — Anti-angiogenesis — Apoptosis

One approach to control the growth of cancer is chemoprevention, in which the disease is prevented, slowed, or reversed by administration of one or more naturally occurring or synthetic compounds. Several studies have shown that microchemicals in the diet, as well as some herbs and plants, can be used for the prevention and/or treatment of various carcinomas.¹⁻⁷ Among them, polyphenolic antioxidant,⁴⁻⁷ a naturally occurring antioxidant that has attracted increasing attention in recent years, can prevent, slow, and/or reverse the induction of cancer and its subsequent development.¹⁻⁶, ⁸

Angiogenesis is activated during multistage tumorigenesis and tumors cannot grow to more than 2–3 mm in diameter without forming new blood vessels.⁹ Thus, one may infer that the growth and metastasis of solid tumors can be suppressed by inhibiting angiogenesis. It has been reported that lipid oxidation products can alter growth factor production, which could influence smooth muscle cell proliferation.¹⁰ Oxidized low density lipoprotein (LDL) can influence smooth muscle cell proliferation by enhancing the expression of platelet-derived growth factor (PDGF)-AA gene and PDGF receptor in vascular smooth muscle cell.¹¹, ¹² Antioxidant is considered to protect lipids and LDL from oxidation, which would potentially inhibit angiogenesis.

Free radical reactions can lead to irreversible alterations of genomic constituents during the initiation phase of carcinogenesis.¹³, ¹⁴ Two experimental approaches have provided evidence of the involvement of free radicals in neoplasia. One is the modulation of cellular antioxidant status and the second is suppression of tumorigenesis by antioxidants.¹⁵ If radicals are instrumental in mediating cell damage, their rapid removal by antioxidants should provide cytoprotection.¹³, ¹⁴ Very strong antioxidant compounds are capable of scavenging both free radicals and reactive oxygen species (ROS, O₂⁻, -OH and H₂O₂), and thus increase the antioxidant potential of cells by ameliorating the deleterious effects of free radical reactions.¹⁶, ¹⁷

Probucol is a very strong synthetic antioxidant, more than three times stronger than vitamin E,¹⁸ and has been used for the treatment of hyperlipidemia in Japan since 1985. Some antioxidants induced apoptosis in Yoshida Sarcoma cells, e.g., Tempicol-2,¹⁹ inhibited cell cycle proliferation in human breast carcinoma cells, e.g., Silymarin,²⁰ and reduced cyclooxygenase-2 expression and prostaglandin production in human colorectal cancer cells.²¹ To investigate whether antioxidants can have an antitumor effect, we studied a head and neck carcinoma cell line (KB,²² which is frequently used for head and

¹To whom requests for reprints should be addressed.
E-mail: go_c@med.yokohama-cu.ac.jp
Antitumor Effect of Probucol in Squamous Carcinoma Xenografts

neck carcinoma investigations) xenografted into mice, and assessed the effects of probucol on tumor growth.

MATERIALS AND METHODS

Materials  Probucol was a kind gift from Daiichi Pharmaceutical Industries (Tokyo). Female 5-week-old athymic nude mice (BALB/c nu/nu) were purchased from Charles River Japan, Inc. (Atsugi). The animals were housed in plastic cages (five mice per cage) with wood chip bedding in a room kept at 24±2°C with a humidity of 40–70% and a 12-h light/dark cycle.

Cell line  KB cells, a human oral floor squamous carcinoma cell line, were grown in RPMI-1640 medium (Life Technologies, Inc., Rockville, MD) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37°C in a 5% CO₂ atmosphere.

Assay of cell proliferation  KB cells were seeded into a 96-well plate (Falcon; Becton Dickinson Labware, Franklin Lakes, NJ) at 1×10³ cells/well in RPMI-1640 medium containing 10% FCS, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37°C in a 5% CO₂ atmosphere.

Assay of cell viability  KB cells were seeded into a 10-cm plastic dish (Falcon) at 1×10⁶ cells/well in RPMI-1640 medium containing 10% FCS. After 48 and 72 h of treatment with probucol (10⁻⁴–10⁻⁸ M), the number of cells was quantitated by an assay using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT; Sigma Chemical Co., St. Louis, MO).

Cell cycle analysis  KB cells at 80–90% confluency were left untreated, treated with ethanol alone, or treated with 10⁻⁵ and 10⁻⁶ M probucol in ethanol. After 48 and 72 h, the medium was removed and the cell monolayers were quickly washed twice with cold phosphate-buffered saline (PBS). Then the cells were trypsinized and cell pellets were collected. The cells were washed twice with PBS, fixed in cold methanol, and washed with PBS to remove methanol. They were suspended in 500 µl of PBS, then digested with 20 µg/ml RNase at 37°C for 30 min and chilled on ice for 10 min. Then cellular DNA was stained with 50 µg/ml propidium iodide by incubation for 1 h at room temperature in the dark. The cell cycle distribution was analyzed by flow cytometry using a Becton Dickinson FACScan.

In vivo tumor growth assay  Because probucol was effective for vasculature disorders, e.g., arterial sclerosis, we thought that it might have some effect on tumor peripheral vessels, and hence on tumor growth. KB cells (5×10⁶) were injected subcutaneously into the left flanks of mice. The tumor size was measured once a week by determining two perpendicular dimensions with calipers, and the volume in mm³ was calculated from the formula (a×b²)/2, where a is the longer and b is the smaller dimension. Two weeks after inoculation, the tumors had grown to 600 mm³ in volume. Then the mice were randomly divided into three groups of 5 animals, which received 0, 50, or 100 mg/kg of probucol, suspended in a 0.5% (w/v) hydroxypropylmethylcellulose (Shinetsu Chemical Co., Nagano) solution, five times per week orally. Because the tumors of control mice were so large at 8 weeks, the animals were killed under anesthesia. At the termination of the investigation, the tumor weight was determined.

Immunohistochemistry  Paraffin-embedded tumor sections were deparaffinized in xylene and rinsed in absolute ethanol. After treatment with 0.3% hydrogen peroxide, the sections were incubated in 1% Bandeiraea simplicifolia agglutinin for 20 min, and then incubated with an anti-factor VIII rabbit monoclonal antibody (Nichirei, Tokyo) and an anti-Ki 67 rabbit monoclonal antibody (Immunotech, Marseille, France). Next, the sections were incubated with biotinylated goat antirabbit immunoglobulin, followed by peroxidase-conjugated streptavidin (ABC kit; Nichirei). Reaction products were visualized by treatment with diaminobenzidine and the sections were examined under a microscope after counterstaining with hematoxylin.

Investigation of apoptosis  Tumors were minced in cold Tris-buffered saline and homogenized. Then the homogenates were filtered and washed with cold Tris-buffered saline, followed by resuspension in 500 µl of lysis buffer

Fig. 1. Probucol treatment showed no effect on cell proliferation in either a dose- or time-dependent manner. □, 48 h; ○, 72 h; ●, 96 h.
containing 500 mM Tris-HCl (pH 9.0), 2 mM EDTA, 10 mM NaCl, 1% sodium dodecyl sulfate, and 1 mg/ml proteinase K (Wako Chemical Co., Osaka). After incubation at 50°C for 20 h, samples were extracted twice with phenol, once with phenol-chloroform, and finally with chloroform. Then aliquots (1 µg) were loaded on 1.5% agarose gels and visualized by ethidium bromide staining. The terminal deoxynucleotidyl transferase-mediated cUDP nick end labeling (TUNEL) method was performed using an Apop Taq Plus kit (Oncor, Gaithersburg, MD) for tumor sections. Counting of immunoreactive tumor cells was done in three different fields for each section, and the apoptotic index was expressed as the percentage of TUNEL-positive cells relative to the total number of cells.

Statistical analysis One-way ANOVA, Sigma Stat for Windows, version 1.0, was used to compare different groups at the 95% confidence level. Student’s t-test was also used to obtain P values and to compare different treatment groups, with P≤0.05 being considered statistically significant.

RESULTS

In vitro effect of probucol Using the MTT assay, we first assessed whether probucol had an antiproliferative effect on KB cells. Probucol treatment showed no dose- or time-dependent effect on cell proliferation (Fig. 1). In addition, cell viability was examined after probucol treatment at 10⁻⁵ and 10⁻⁶ M for 48 and 72 h. It was found that probucol had no effect on cell viability and that almost all cells (98.1–99.2%) remained alive. The influence of probucol on the cell cycle was assessed using flow cytometry, and again there was no effect of treatment (data not shown). Thus, probucol seemed to have no effect on KB cells in vitro.
In vivo effect of probucol  Male nude mice underwent inoculation with KB cells on day 0 and probucol was administered orally from day 14 (five times/week) at doses of 50 and 100 mg/kg for 8 weeks. Treatment of tumor-bearing nude mice with probucol had no significant effect on the body weight at any dose administered (data not shown). The slight loss of weight observed in the treated animals was a result of the decreased tumor weight caused by the antitumor effect of the drug. The effect of probucol on KB cell xenografts growing in nude mice is shown in Fig. 2A and tumor weights at the termination of treatment are shown in Fig. 2B. Probucol treatment resulted in significant suppression of tumor growth when control mice were compared with those given 100 mg/kg of probucol \((P<0.05)\). There was no significant difference between control mice and those given 50 mg/kg of probucol or between 50 mg/kg and 100 mg/kg of probucol, but tumor growth (volume and weight) tended to be suppressed by probucol at 50 mg/kg. Macroscopic evaluation showed that the tumors of treated mice developed ulcers at the beginning of the 6th week and the change was dose-dependent. In contrast, the untreated control mice showed no ulceration of their tumors.

Immunohistochemistry  To evaluate the anti-angiogenic effect of probucol, the tumor was immunohistochemically stained with anti-human factor VIII. Tumor microvessels in the peripheral region of tumors, positive for anti-human factor VIII, were observed in every group and the number was significantly less in the group given 100 mg/kg of probucol (Fig. 3). The number in the group treated with 50 mg/kg was somewhat less than in the control, but the difference was not significant. To assess the effect on the cell cycle in vivo, immunohistochemical staining with anti-human Ki 67 (MIB-1) antibody was done. This antibody
stains S+G2 and M phase cycle cells. Ki 67-positive cells were observed in every group; about 70% (68.3–71.8%) of viable tumor cells were positive and the positivity rate was not significantly different among the groups. Because KB cells do not express cyclin D1,24) immunohistochemical staining with anti-cyclin D1 was not done for cell cycle analysis.

**Apoptosis** We also examined whether treatment of tumor-bearing mice with probucol was able to cause apoptotic cell death *in vivo*. Probucol treatment resulted in an increase of TUNEL-positive cells (Fig. 4A). Quantitative data are summarized in Fig. 4B. The apoptotic index was significantly higher in mice treated with 50 mg/kg and 100 mg/kg of probucol as compared with untreated control mice. The results of DNA fragmentation analysis are shown in Fig. 4C. DNA was degraded to oligonucleosomal DNA fragments that showed apoptotic laddering on agarose gel electrophoresis when tumor-bearing mice were treated with 100 mg/kg of probucol, whereas such laddering was not observed in untreated mice given 50 mg/kg or untreated control mice (C). *P<0.05; bars, SD; arrow, TUNEL-positive cells; scale, 50 μm.

Fig. 4. TUNEL-positive cells were increased in the probucol treatment group (A: a, control; b, 100 mg/kg). Quantitative data are summarized in B. The apoptotic index was significantly higher in tumors from mice that had been treated at a dose of 50 and 100 mg/kg with probucol as compared with untreated control ones. DNA was degraded to oligonucleosomal DNA fragments that showed apoptotic laddering on agarose gel electrophoresis when tumor-bearing mice were treated with 100 mg/kg of probucol, whereas such laddering was not observed in mice given 50 mg/kg or untreated control mice (C). *P<0.05; bars, SD; arrow, TUNEL-positive cells; scale, 50 μm.
DISCUSSION

The concept of systematic administration of compounds that exhibit antioxidant activity is appealing. Efforts are being made to identify naturally occurring antioxidants, e.g. polyphenolic antioxidants, which can prevent, slow, and/or reverse the processes of carcinogenesis and tumor development. Agents which possess strong antioxidant properties may be useful for preventing tumorigenesis and tumor growth, because free radical reactions can give rise to irreversible alterations of cellular genomic constituents related to the initiation phase of carcinogenesis. Protection against the initiation of cancer may be provided by antioxidant supplements because tumor cells usually show reduced activity of their primary cell defense system. The involvement of oxidative stress in the induction of cancer and its subsequent development is becoming increasing clear, as are the associated molecular mechanisms. e.g., modulation of the cellular antioxidant status, and suppression of tumorigenesis by antioxidants.

Probucol is a strong antioxidant (more than 3 times stronger than vitamin E) and it has been clinically used for the treatment of hyperlipidemia in Japan since 1985. As a therapeutic agent, it is well tolerated and largely free from side effects. It has been shown to be nontoxic in acute, subacute, and chronic toxicity studies even at high doses. Probucol is effective for inhibiting restenosis after percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction patients. The process of restenosis after PTCA involves smooth muscle cell proliferation, extracellular matrix formation and vascular remodeling. There is considerable evidence to suggest that oxidative stress plays an important role in the restenosis process. It has been demonstrated that lipid oxidation products can alter growth factor production, which could influence smooth muscle cell proliferation. Oxidized LDL has been shown to be a chemoattractant for smooth muscle cells and a stimulant of smooth muscle cell proliferation. It enhances PDGF-AA gene expression and PDGF receptor expression in vascular smooth muscle cell. Probucol has a superoxide free radical scavenging effect and inhibits the production of PDGF, and also protects LDL from oxidation, which potentially reduces smooth muscle cell proliferation. In this study, tumor growth was significantly suppressed in probucol-treated mice compared with that in untreated mice. Probucol did not directly act on KB cells in vitro, but an antitumor effect was observed in tumor-bearing mice via an anti-angiogenic action, which might induce macroscopic ulceration and cellular apoptosis as a result of decreasing blood supply.

Oxidative stress is an important contributor to carcinogenesis. Considering its lack of effect on the cell cycle in vivo, probucol should not influence KB cell viability or inhibit carcinogenesis in an advanced model. But as an antioxidant, probucol could scavenge ROS and free radicals by terminating biological reactions that generate them and/or preventing depletion of the antioxidant system in an early-phase model. Additional studies are needed. The significant inhibitory effect of probucol on KB cell xenografts in mice suggests that its strong antioxidant activity may have an anti-angiogenic effect, leading to apoptosis in vivo. These results suggest that probucol could be a useful tumor-preventing agent for human head and neck squamous cell carcinoma.

ACKNOWLEDGMENTS

We thank Daiichi Pharmaceutical Industries (Tokyo) for the kind gift of probucol.

(Received May 28, 1999/Revised August 16, 1999/Accepted August 24, 1999)

REFERENCES

1) Wattenberg, L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res., 52, 2085–2091 (1992).
2) Morse, M. A. and Stoner, G. D. Cancer chemoprevention: principles and prospects. Carcinogenesis (Lond.), 14, 1737–1746 (1993).
3) Boone, C. W. and Wattenberg, L. W. Current strategies of cancer chemoprevention: 13th Sapporo Cancer Seminar. Cancer Res., 54, 3315–3318 (1994).
4) Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R. and Signen, C. C. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol. Biomarkers Prev., 3, 85–98 (1994).
5) Agawal, R. and Mukhtar, H. Cancer chemoprevention by polyphenolic compounds present in green tea. Drug News Perspect., 8, 216–225 (1995).
6) Ames, B. N., Gold, L. S. and Willett, W. C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA, 92, 5258–5265 (1995).
7) Stoner, G. D., Morse, M. A. and Kelloff, G. J. Perspectives in cancer chemoprevention. Environ. Health Perspect., 105, 945–954 (1997).
8) Wei, H., Tye, L., Bresnick, E. and Brit, D. F. Inhibition effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res., 50, 499–502 (1990).
9) Hanahan, D. and Folkman, J. Pattern and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353–364 (1996).
10) Ku, G., Doherty, N. S., Wolos, J. A. and Jackson, L. R. Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. *Am. J. Cardiol.*, **62**, 77B–81B (1988).

11) Cushing, S. D., Berliner, J. A., Valente, A. J., Territo, M. C., Navah, M., Parhami, F., Gerrity, R., Schwartz, C. J. and Fogelman, A. M. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. *Proc. Natl. Acad. Sci. USA*, **87**, 5134–5138 (1990).

12) Stiko-Rahm, A., Hultgardh-Nilsson, A., Regnstrom, J., Hamsten, A. and Nilsson, J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. *Arterioscler. Thromb.*, **12**, 1099–1109 (1992).

13) Sun, Y. Free radicals, antioxidant enzymes and carcinogenesis. *Free Radic. Biol. Med.*, **8**, 583–599 (1990).

14) Yu, B. P. Cellular defences against damage from reactive oxygen species. *Physiol. Rev.*, **74**, 139–162 (1994).

15) Okada, S. Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. *Pathol. Int.*, **46**, 311–332 (1996).

16) Valenzuela, A., Guerra, R. and Videla, L. A. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene. *Planta Med.*, **52**, 438–440 (1986).

17) Comoglio, A., Leonarduzzi, G., Carini, R., Busolin, D., Basaga, H., Albano, E., Tomasi, A., Poli, G., Morazzoni, P. and Magistretti, M. J. Studies on the antioxidant and free radical scavenging properties of IdB 1016: a new flavanolignan complex. *Free Radic. Res. Commun.*, **11**, 109–115 (1990).

18) Kontush, A., Djahansouzi, S., Braesen, J. H., Kohlschutter, A. and Beisiegel, U. Physiological doses of chemically defined LDL mimics of minimally modified LDL: effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G, arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. *Clin. Cancer Res.*, **4**, 1055–1064 (1998).

19) Whinery, R., Beauchamp, R. D., Shyr, Y., Kirkland, S. C., Coffey, R. J. and Morrow, J. D. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. *Cancer Res.*, **58**, 2323–2327 (1998).

20) Eagle, H. Propagation in fluid medium of a human epidermoid carcinoma, strain KB. *Proc. Soc. Exp. Biol. Med.*, **89**, 362–364 (1955).

21) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods*, **65**, 55–63 (1983).

22) Zhou, L.-X. Biological behavior of hypopharyngeal carcinoma. *J. Otolaryngol. Jpn.*, **100**, 59–67 (1997).

23) Gonzalez, M. J. and Riordan, N. H. The paradoxical role of lipid peroxidation in carcinogenesis and tumor growth: a commentary. *Med. Hypotheses*, **46**, 503–504 (1996).

24) Bozzi, A., Mavelli, J., Mondevi, B., Strom, R. and Rotilio, G. Differential cytoxicity of daunomycin in tumor cells is related to glutathione-dependent hydrogen peroxide metabolism. *Biochem. J.*, **194**, 369–372 (1981).

25) Sen, C. K. and Packer, L. Antioxidant and redox regulation of gene transcription. *FASEB J.*, **10**, 709–720 (1996).

26) Yokoi, H., Daida, H., Kuwabara, Y., Nishikawa, H., Takatsu, F., Tomihara, H., Nakata, Y., Kutsumi, Y., Ohshima, S., Nishiyama, S., Seki, A., Kato, K., Nishimura, S., Kanoh, T. and Yamaguchi, H. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial. *J. Am. Coll. Cardiol.*, **30**, 855–862 (1997).

27) Wilcox, J. N. Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. *Am. J. Cardiol.*, **72**, 85E–95E (1993).

28) Pathak, M. A. and Stratton, K. Free radicals in human skin before and after exposure to light. *Arch. Biochem. Biophys.*, **123**, 468–476 (1968).

29) Taits, J., Mimura, K., Yoneya, T., Hagi, A., Murakami, A. and Makino, K. Hydroxyl radical formation by UV-irradiated epidermal cells. *J. Biochem.*, **111**, 693–695 (1992).

30) Shindo, Y., Witt, E. and Packer, L. Antioxidant defense mechanisms in murine epidermis and their responses to ultraviolet light. *J. Invest. Dermatol.*, **100**, 260–265 (1993).

31) Mukhtar, H. and Elmets, C. A. Photocarcinogenesis: mechanisms, models and human health implications. *Photochem. Photobiol.*, **63**, 356–357 (1996).

32) Tyrrell, R. M. Oxidant, antioxidant status and photocarcinogenesis: the role of gene activation. *Photochem. Photobiol.*, **63**, 380–383 (1996).

33) Agarwal, R., Katiyar, S. K., Khan, S. G. and Mukhtar, H. Protection against ultraviolet B radiation-induced effects in skin of SKH-1 hairless mice by a polyphenolic fraction isolated from green tea. *Photochem. Photobiol.*, **58**, 695–700 (1993).

34) Katiyar, S. K., Korman, N. J., Mukhtar, H. and Agarwal, R. Protective effects of silimarin against photocarcinogenesis in a mouse skin model. *J. Natl. Cancer Inst.*, **89**, 556–566 (1997).